Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Merck places children's HIV drug in shared non-profit patent pool

U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap pediatric formulations for use in poor countries.

Published
24 February 2015
From
Reuters
Critiquing UNAIDS HIV Prevention Goals, AVAC Calls For Honed Strategy

The global HIV advocacy group AVAC has raised an alarm that global goals for HIV prevention may prove ineffectual due to their vagueness.

Published
24 February 2015
From
AIDSMeds
US: 91% of HIV Passes From Those Unaware They're Infected or Not in Care

The research suggests that as individuals make their way through the steps of the treatment cascade, their average risk of transmitting HIV drops off steadily. An estimated 91.5 percent of new HIV transmits from people who do not know they are infected or who are not in medical care for the virus.

Published
23 February 2015
From
AIDSMeds
Annual epidemiological report 2014 - Sexually transmitted infections, including HIV and blood-borne viruses

The annual report provides an overview of the epidemiology of chlamydia, gonorrhoea, hepattis B and C, HIV, AIDS and syphilis based on 2012 data.

Published
20 February 2015
From
European Centre for Disease Prevention and Control
amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

Published
19 February 2015
From
amfAR
The Drug That Is Bankrupting America

With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

Published
18 February 2015
From
Huffington Post
Fighting tuberculosis in the European region requires urgent support. Take action today!

Today, the TB Europe Coalition, with the support of Stop TB Partnership, launches the Fight TB 2015 campaign to ensure that European leaders step up their response to TB to save millions of lives.

Published
18 February 2015
From
TB Europe Coalition
Migrant primary care charge proposals shelved... for now...

Migrant rights campaigners can celebrate this week. It seems that ongoing lobbying has led the Department of Health to kick plans for new primary care charges for migrants into the long grass... Now we need to make sure they don't return in the autumn to haunt us.

Published
16 February 2015
From
Migrants' Rights Network
The Search for a Permanent Alternative to HIV Drugs

Researchers Carefully Tailor a Study to Find Patients to Test Going Off Antiretroviral Medication

Published
16 February 2015
From
Wall Street Journal
Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again

PatientView surveyed 1,150 patient groups from 58 countries and asked them about the corporate reputation of 37 pharma companies. The respondents ranked ViiV Healthcare number one across the board. Gilead fell from the #2 ranking position in 2013 to #14 in 2014—likely a consequence of the controversially high prices for specialty hep C meds.

Published
16 February 2015
From
Bio Pharma Dive

Filter by country